Literature DB >> 21960503

Quantitative blood flow measurements in gliomas using arterial spin-labeling at 3T: intermodality agreement and inter- and intraobserver reproducibility study.

T Hirai1, M Kitajima, H Nakamura, T Okuda, A Sasao, Y Shigematsu, D Utsunomiya, S Oda, H Uetani, M Morioka, Y Yamashita.   

Abstract

BACKGROUND AND
PURPOSE: QUASAR is a particular application of the ASL method and facilitates the user-independent quantification of brain perfusion. The purpose of this study was to assess the intermodality agreement of TBF measurements obtained with ASL and DSC MR imaging and the inter- and intraobserver reproducibility of glioma TBF measurements acquired by ASL at 3T.
MATERIALS AND METHODS: Two observers independently measured TBF in 24 patients with histologically proved glioma. ASL MR imaging with QUASAR and DSC MR imaging were performed on 3T scanners. The observers placed 5 regions of interest in the solid tumor on rCBF maps derived from ASL and DSC MR images and 1 region of interest in the contralateral brain and recorded the measured values. Maximum and average sTBF values were calculated. Intermodality and intra- and interobsever agreement were determined by using 95% Bland-Altman limits of agreement and ICCs.
RESULTS: The intermodality agreement for maximum sTBF was good to excellent on DSC and ASL images; ICCs ranged from 0.718 to 0.884. The 95% limits of agreement ranged from 59.2% to 65.4% of the mean. ICCs for intra- and interobserver agreement for maximum sTBF ranged from 0.843 to 0.850 and from 0.626 to 0.665, respectively. The reproducibility of maximum sTBF measurements obtained by methods was similar.
CONCLUSIONS: In the evaluation of sTBF in gliomas, ASL with QUASAR at 3T yielded measurements and reproducibility similar to those of DSC perfusion MR imaging.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21960503      PMCID: PMC7964416          DOI: 10.3174/ajnr.A2725

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  32 in total

1.  Simultaneous noninvasive measurement of CBF and CBV using double-echo FAIR (DEFAIR).

Authors:  D L Thomas; M F Lythgoe; F Calamante; D G Gadian; R J Ordidge
Journal:  Magn Reson Med       Date:  2001-05       Impact factor: 4.668

2.  Model-free arterial spin labeling quantification approach for perfusion MRI.

Authors:  Esben Thade Petersen; Tchoyoson Lim; Xavier Golay
Journal:  Magn Reson Med       Date:  2006-02       Impact factor: 4.668

Review 3.  Theoretical basis of hemodynamic MR imaging techniques to measure cerebral blood volume, cerebral blood flow, and permeability.

Authors:  G Zaharchuk
Journal:  AJNR Am J Neuroradiol       Date:  2007 Nov-Dec       Impact factor: 3.825

4.  High-grade and low-grade gliomas: differentiation by using perfusion MR imaging.

Authors:  B Hakyemez; C Erdogan; I Ercan; N Ergin; S Uysal; S Atahan
Journal:  Clin Radiol       Date:  2005-04       Impact factor: 2.350

5.  The QUASAR reproducibility study, Part II: Results from a multi-center Arterial Spin Labeling test-retest study.

Authors:  Esben Thade Petersen; Kim Mouridsen; Xavier Golay
Journal:  Neuroimage       Date:  2009-08-04       Impact factor: 6.556

Review 6.  Arterial spin-labeling in routine clinical practice, part 3: hyperperfusion patterns.

Authors:  A R Deibler; J M Pollock; R A Kraft; H Tan; J H Burdette; J A Maldjian
Journal:  AJNR Am J Neuroradiol       Date:  2008-03-20       Impact factor: 3.825

7.  Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas.

Authors:  T Sugahara; Y Korogi; M Kochi; I Ikushima; T Hirai; T Okuda; Y Shigematsu; L Liang; Y Ge; Y Ushio; M Takahashi
Journal:  AJR Am J Roentgenol       Date:  1998-12       Impact factor: 3.959

8.  Doppler perfusion index: an interobserver and intraobserver reproducibility study.

Authors:  K Oppo; E Leen; W J Angerson; T G Cooke; C S McArdle
Journal:  Radiology       Date:  1998-08       Impact factor: 11.105

Review 9.  Arterial spin-labeling in routine clinical practice, part 1: technique and artifacts.

Authors:  A R Deibler; J M Pollock; R A Kraft; H Tan; J H Burdette; J A Maldjian
Journal:  AJNR Am J Neuroradiol       Date:  2008-03-27       Impact factor: 3.825

10.  Perfusion imaging of brain tumors using arterial spin-labeling: correlation with histopathologic vascular density.

Authors:  T Noguchi; T Yoshiura; A Hiwatashi; O Togao; K Yamashita; E Nagao; T Shono; M Mizoguchi; S Nagata; T Sasaki; S O Suzuki; T Iwaki; K Kobayashi; F Mihara; H Honda
Journal:  AJNR Am J Neuroradiol       Date:  2008-01-09       Impact factor: 3.825

View more
  24 in total

1.  Comparative study of pulsed-continuous arterial spin labeling and dynamic susceptibility contrast imaging by histogram analysis in evaluation of glial tumors.

Authors:  Atsuko Arisawa; Yoshiyuki Watanabe; Hisashi Tanaka; Hiroto Takahashi; Chisato Matsuo; Takuya Fujiwara; Masahiro Fujiwara; Yasunori Fujimoto; Noriyuki Tomiyama
Journal:  Neuroradiology       Date:  2018-04-29       Impact factor: 2.804

2.  3D GRASE pulsed arterial spin labeling at multiple inflow times in patients with long arterial transit times: comparison with dynamic susceptibility-weighted contrast-enhanced MRI at 3 Tesla.

Authors:  Steve Z Martin; Vince I Madai; Federico C von Samson-Himmelstjerna; Matthias A Mutke; Miriam Bauer; Cornelius X Herzig; Stefan Hetzer; Matthias Günther; Jan Sobesky
Journal:  J Cereb Blood Flow Metab       Date:  2014-11-19       Impact factor: 6.200

3.  Perfusion imaging of brain gliomas using arterial spin labeling: correlation with histopathological vascular density in MRI-guided biopsies.

Authors:  Di Ningning; Pang Haopeng; Dang Xuefei; Cheng Wenna; Ren Yan; Wu Jingsong; Yao Chengjun; Yao Zhenwei; Feng Xiaoyuan
Journal:  Neuroradiology       Date:  2016-12-06       Impact factor: 2.804

4.  Prognostic value of blood flow estimated by arterial spin labeling and dynamic susceptibility contrast-enhanced MR imaging in high-grade gliomas.

Authors:  Mandy Kim Rau; Christian Braun; Marco Skardelly; Jens Schittenhelm; Frank Paulsen; Benjamin Bender; Ulrike Ernemann; Sotirios Bisdas
Journal:  J Neurooncol       Date:  2014-08-27       Impact factor: 4.130

5.  Arterial spin-labeled perfusion of pediatric brain tumors.

Authors:  K W Yeom; L A Mitchell; R M Lober; P D Barnes; H Vogel; P G Fisher; M S Edwards
Journal:  AJNR Am J Neuroradiol       Date:  2013-08-01       Impact factor: 3.825

6.  Reduced regional cerebral blood flow in patients with heart failure.

Authors:  Bhaswati Roy; Mary A Woo; Danny J J Wang; Gregg C Fonarow; Ronald M Harper; Rajesh Kumar
Journal:  Eur J Heart Fail       Date:  2017-05-30       Impact factor: 15.534

7.  Heterogeneity of cortical lesions in multiple sclerosis: an MRI perfusion study.

Authors:  Denis Peruzzo; Marco Castellaro; Massimiliano Calabrese; Elisa Veronese; Francesca Rinaldi; Valentina Bernardi; Alice Favaretto; Paolo Gallo; Alessandra Bertoldo
Journal:  J Cereb Blood Flow Metab       Date:  2012-12-19       Impact factor: 6.200

8.  Comparison of multiple parameters obtained on 3T pulsed arterial spin-labeling, diffusion tensor imaging, and MRS and the Ki-67 labeling index in evaluating glioma grading.

Authors:  H Fudaba; T Shimomura; T Abe; H Matsuta; Y Momii; K Sugita; H Ooba; T Kamida; T Hikawa; M Fujiki
Journal:  AJNR Am J Neuroradiol       Date:  2014-07-03       Impact factor: 3.825

9.  Comparative analysis of arterial spin labeling and dynamic susceptibility contrast perfusion imaging for quantitative perfusion measurements of brain tumors.

Authors:  Jingjing Jiang; Lingyun Zhao; Yan Zhang; Shun Zhang; Yihao Yao; Yuanyuan Qin; Cong-Yi Wang; Wenzhen Zhu
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

10.  Arterial spin labeling: Pathologically proven superiority over conventional MRI for detection of high-grade glioma progression after treatment.

Authors:  Eric Nyberg; Justin Honce; Bette K Kleinschmidt-DeMasters; Brian Shukri; Sarah Kreidler; Lidia Nagae
Journal:  Neuroradiol J       Date:  2016-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.